What is voclosporin used for?
Voclosporin is used to treat active lupus nephritis. It is a calcineurin inhibitor that changes the immune system to help control lupus symptoms. This medicine is available only with your doctor’s prescription.
What type of drug is voclosporin?
Voclosporin belongs to a class of drugs known as immunosuppressants. It works by weakening the immune system to help decrease damage to your kidneys.
Is voclosporin FDA approved?
In January, the FDA approved voclosporin (Lupkynis), a calcineurin inhibitor, to be used in combination with background immunosuppressive therapy to treat adults with active lupus nephritis.
How long do you take Lupkynis?
LUPKYNIS should be taken on an empty stomach consistently as close to a 12-hour schedule as possible, and with a minimum of 8 hours between doses….
| Adverse Reaction | LUPKYNIS 23.7 mg twice a day (n=267) | Placebo (n=266) |
|---|---|---|
| Cough | 11% | 2% |
| Urinary tract infection | 10% | 6% |
| Abdominal pain upper | 7% | 2% |
| Dyspepsia | 6% | 3% |
Is voclosporin approved in Canada?
” Voclosporin will improve people’s lives; it’s a breakthrough for people living with lupus.” Medical treatments for lupus are rare. Volcosporin is only the second treatment to come to market to treat lupus in more than 60 years. It is not yet approved for use in Canada.
Does Lupkynis work?
By binding to calcineurin, Lupkynis stops T cells from triggering an autoimmune response, reducing inflammation in the kidneys. Large clinical trials of Lupkynis showed it was better and faster at preventing inflammation of the kidneys than standard of care treatment.
Is voclosporin approved in Europe?
In December 2020, Aurinia Pharmaceuticals and Otsuka Pharmaceuticals entered a collaboration and license agreement for the development and commercialization of oral voclosporin as a treatment for LN in the European Union, Japan, United Kingdom, Russia, Switzerland, Norway, Belarus, Iceland, Liechtenstein, and Ukraine.
When was voclosporin FDA approved?
Development Timeline for Lupkynis
| Date | Article |
|---|---|
| Jan 22, 2021 | Approval FDA Approves Lupkynis (voclosporin) for Adult Patients with Active Lupus Nephritis |
When was belimumab FDA approved?
On March 9, 2011, the U.S. Food and Drug Administration (FDA) approved the use of Benlysta® (belimumab), developed by Human Genome Sciences (HGS) and GlaxoSmithKline (GSK), in systemic lupus erythematosus patients with active disease despite standard treatment.
What does Lupkynis treat?
Lupkynis is a drug developed to treat lupus nephritis, a lupus-related kidney disease caused by inflammation. It is taken as a pill in combination with standard of care therapies and works by suppressing the immune system.
What is the new medication for lupus?
A new biologic for systemic lupus erythematosus may help reduce corticosteroid use. People living with systemic lupus erythematosus (SLE) have a new drug option. The U.S. Food and Drug Administration approved anifrolumab (Saphnelo) in early August — the first new drug approved for SLE in 10 years.